膜杰作
Star Staining
分子别名（Synonym）
CD158b1
表达区间及表达系统（Source）
Human KIR2DL2, Fc Tag (KI2-H5255) is expressed from human 293 cells (HEK293). It contains AA His 22 - His 245 (Accession # P43627-1).
Predicted N-terminus: His 22
Request for sequence
蛋白结构（Molecular Characterization）
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 51.0 kDa. The protein migrates as 60-70 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
内毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
纯度（Purity）
>95% as determined by SDS-PAGE.
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 25 mM Arginine, 150 mM NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
电泳（SDS-PAGE）
Human KIR2DL2, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
活性（Bioactivity）-ELISA
Immobilized Human KIR2DL2, Fc Tag (Cat. No. KI2-H5255) at 1 μg/mL (100 μL/well) can bind Lirilummab with a linear range of 0.2-8 ng/mL (QC tested).
Protocol
活性（Bioactivity）-SPR
Biotinylated Biotinylated Human HLA-C*07:02:01 & B2M & RYR ,His,Avitag™&Tag Free (Cat. No. HLR-H52W2) immobilized on SA Chip can bind Human KIR2DL2, Fc Tag (Cat. No. KI2-H5255) with an affinity constant of 1.01 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Protocol
背景（Background）
Killer cell immunoglobulin-like receptor 2DL2(KIR2DL2), which belongs to the immunoglobulin superfamily, is an inhibitory receptor of NK cells. KIR2DL2 and KIR2DL3, regulate the activation of natural killer cells (NK) by interacting with the human leukocyte antigen-C1 (HLA-C1) group of molecules. KIR2DL2, KIR2DL3 and HLA-C1 are highly polymorphic, with this variation being associated with differences in the onset and progression of some human diseases.
